Location History:
- Navarra, ES (2014)
- Pamplona, ES (2015 - 2022)
Company Filing History:
3 out of 10 
2 out of 870 
2 out of 1,743 
Years Active: 2014-2025
Title: Innovations by Pedro Berraondo Lopez: Pioneering mRNA Therapy for Acute Intermittent Porphyria
Introduction
Pedro Berraondo Lopez is a distinguished inventor based in Pamplona, Spain, known for his significant contributions to the field of medical research. With a portfolio of six patents, he has established himself as a key figure in biomedicine, particularly in the development of innovative therapies targeting rare genetic disorders.
Latest Patents
Among his remarkable inventions are two notable patents related to the treatment of Acute Intermittent Porphyria (AIP). The first patent focuses on polynucleotides encoding porphobilinogen deaminase, crucial for mRNA therapy. This innovative therapy aims to encode human porphobilinogen deaminase (PBGD) and its isoforms, facilitating enhanced expression and activity of PBGD in patients affected by AIP. The application of lipid nanoparticles (LNPs) in this mRNA therapy ensures efficient delivery to cells, which is central to combating toxic metabolite accumulation linked to deficient PBGD activity.
The second patent discloses methods regarding human porphobilinogen deaminase derived proteins and polynucleotides, further expanding the therapeutic possibilities for AIP and potentially other metabolic disorders.
Career Highlights
Pedro has garnered rich professional experience at prominent research institutions, including the Fundación Para La Investigación Médica Aplicada and the Institut Pasteur. His work often blends cutting-edge science with practical applications, aimed at improving patient outcomes through advanced treatment methodologies.
Collaborations
Throughout his career, Pedro Berraondo Lopez has collaborated with distinguished professionals in the field, including Claude Leclerc and Antonio Fontanellas Roma. These partnerships have fostered a conducive environment for innovation and have significantly contributed to the successful development of his mRNA-based therapies.
Conclusion
Pedro Berraondo Lopez stands out as an influential inventor whose work in mRNA therapy holds great promise for the treatment of Acute Intermittent Porphyria. His innovative approach not only paves the way for new therapeutic options but also illustrates the impact of dedicated research in addressing complex medical challenges. With a strong foundation of collaborations and a clear vision for the future, Lopez continues to inspire advancements in the field of biomedicine.